Phase 2 study of pembrolizumab in advanced small-cell lung cancer (SCLC): KEYNOTE-158.Hyun Cheol Chung, Sarina A. Piha‐Paul, Jean‐Pierre Delord et al.|Journal of Clinical Oncology|2018Cited by 208